The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
After the first successes of gene therapy for rare genetic diseases, the field has now reached maturity with multiple products registered not only for rare diseases but also for oncology indications, and many more under development. With the rapid development of the field, the issues linked to large-scale manufacturing, industrialization and pricing represent major challenges to allow broad access to patients of these groundbreaking therapies.